Kringle Pharma (4884) · RiskRestated
Risks Relating to the Continuity and Quality Control of Outsourced Manufacturing
First written in FY2020. 1 of 2 entries say "Restated". Latest entry: FY2022.
2entries
3years
0from disclosures
How it moved
Same theme, other companies
Risk of insufficient supply capacity and shutdowns at outsourced production partnersA theme 65 companies write about · 67 as a headwind · 0 as a tailwind
The whole theme swung hardest in 2024: 10 of 32 companies on the "Worse" side.
34 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 65 companies compared. The sentences above are computed from all 65.Full recordFilings, disclosures and news, newest first
- FY2022RestatedAnnual report
「何らかの事情により委託先が当社が製造委託した原薬又は製剤を製造できなくなる可能性があります。」
外部委託先の製造継続不能や品質管理不備のリスクを引き続き開示している。 - FY2020First statedAnnual report
「Our contractors may become unable to manufacture our products for some reason. Although we and our contractors have each established quality control systems and manufacture products of a certain quality, if a product with quality problems is used due to inadequate controls, our reliability may not be maintained and business operations may be disrupted.」
While contract manufacturing reduces fixed costs and provides flexibility, the company identifies contractors’ inability to manufacture and inadequate quality controls as risks.